Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.
This article reviews new vaccination protocols against glioblastoma, as well as new the prospect of novel combination therapies.
Researchers have developed novel mini ‘artificial brains’ to model glioma tumor growth: the organoids could soon be used to develop personalized treatment strategies against brain cancers.
In this Special Report, the authors discuss how the versatility of utilizing cancer-targeting alkylphosphocholine analogs may ultimately transform clinical management of primary and metastatic brain tumors.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
In this study, the authors identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine.
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma
This summary guideline outlines methods for starting patients on TTFields, for monitoring patient response to therapy and provides a framework for evaluating when therapy should be re-planned.
Researchers have identified a metabolic vulnerability in glioblastoma and demonstrated that it could be targeted in new therapies.
A new soluble form of aspirin has shown efficacy against glioblastoma in laboratory tests.
This article reviews the potential of personalized medicine in neuro-oncology, evaluating the molecular–genetic approach and therapies utilizing the cell line.
Researchers have developed an assay that has the potential to measure how quickly glioblastoma tumors will spread.